# ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

> **NCT01218997** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 436 (actual)

## Conditions studied

- Alcoholism

## Interventions

- **DRUG:** Medisorb naltrexone 380 mg
- **DRUG:** Oral naltrexone 50 mg

## Key facts

- **NCT ID:** NCT01218997
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 436 (ACTUAL)
- **Last updated:** 2011-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218997, "ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01218997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*